Loading...
Abiraterone and enzalutamide are widely used as initial therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) both in those managed with androgen deprivation therapy (ADT) alone and in those given docetaxel intensification in the hormone-sensitive metastatic setting. A phase 3 trial of the poly(adenosine diphosphate[ADP]-ribose) polymerase (PARP) inhibitor olaparib demonstrated improvement in both progression-free (PFS) and overall survival (OS) in men with BRCA 1/2 and ATM mutations. A randomized phase 2 study of the combination of abiraterone and olaparib demonstrated provocative activity.
Now, in a double-blind, industry-sponsored phase 3 study, nearly 800 men with mCRPC who had not received prior systemic ther…